NASDAQ:RDUS - Radius Health Stock Price, Price Target & More

$32.74 -0.28 (-0.85 %)
(As of 04/24/2018 12:36 PM ET)
Previous Close$33.02
Today's Range$32.70 - $33.82
52-Week Range$24.66 - $49.16
Volume117,500 shs
Average Volume856,586 shs
Market Capitalization$1.50 billion
P/E Ratio-5.64
Dividend YieldN/A
Beta1.25

About Radius Health (NASDAQ:RDUS)

Radius Health logoRadius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company's clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RDUS
CUSIPN/A
Phone617-551-4000

Debt

Debt-to-Equity Ratio0.69%
Current Ratio5.04%
Quick Ratio4.96%

Price-To-Earnings

Trailing P/E Ratio-5.64
Forward P/E Ratio-6.41
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.11 million
Price / Sales66.75
Cash FlowN/A
Price / CashN/A
Book Value$5.43 per share
Price / Book6.03

Profitability

EPS (Most Recent Fiscal Year)($5.80)
Net Income$-254,230,000.00
Net MarginsN/A
Return on Equity-99.97%
Return on Assets-67.64%

Miscellaneous

Employees561
Outstanding Shares45,080,000

How to Become a New Pot Stock Millionaire

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How were Radius Health's earnings last quarter?

Radius Health (NASDAQ:RDUS) released its quarterly earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, missing the Zacks' consensus estimate of ($1.43) by $0.16. The biopharmaceutical company had revenue of $7.66 million for the quarter, compared to analyst estimates of $7.37 million. Radius Health's quarterly revenue was up 666.0% on a year-over-year basis. During the same period in the previous year, the company posted ($1.22) earnings per share. View Radius Health's Earnings History.

What price target have analysts set for RDUS?

11 brokers have issued 1-year price targets for Radius Health's shares. Their predictions range from $24.00 to $85.00. On average, they anticipate Radius Health's stock price to reach $52.10 in the next twelve months. View Analyst Ratings for Radius Health.

What are Wall Street analysts saying about Radius Health stock?

Here are some recent quotes from research analysts about Radius Health stock:
  • 1. According to Zacks Investment Research, "Radius received a major boost with the approval of Tymlos for the treatment of postmenopausal women with high risk osteoporosis for fracture. Although the osteoporosis market has a great potential as approximately 1.4 million postmenopausal women in the United States experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's Forteo and Amgen’s Prolia. Further, the company suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues to its MAA for Eladynos in Europe. The CHMP will issue a third Day-180 List of Outstanding Issues in its regulatory review of abaloparatide-SC. While Radius' efforts in developing its pipeline are encouraging, we note that most of its candidates are in their early or mid stages of development. The company’ shares have underperformed the industry in the last twelve months." (1/8/2018)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (7/31/2017)
  • 3. Cantor Fitzgerald analysts commented, "RDUS shares are rallying this morning (+2%) on FDA approval of TYMLOS (abaloparatide-SC) ahead of expectations, as the extended PDUFA was June." (4/28/2017)

Who are some of Radius Health's key competitors?

Who are Radius Health's key executives?

Radius Health's management team includes the folowing people:
  • Kurt C. Graves, Independent Chairman of the Board (Age 49)
  • Jesper Hoiland, President, Chief Executive Officer, Director (Age 56)
  • Jose Carmona, Chief Financial Officer, Principal Accounting Officer, Treasurer (Age 45)
  • Gary Hattersley Ph.D., Senior Vice President, Chief Scientific Officer (Age 50)
  • Brent Hatzis-Schoch, Senior Vice President, General Counsel, Secretary (Age 52)
  • Lorraine A. Fitzpatrick M.D., Chief Medical Officer (Age 63)
  • Gregory Williams Ph.D., Chief Development Officer (Age 58)
  • Willard H. Dere M.D., Independent Director (Age 63)
  • Catherine J. Friedman, Independent Director (Age 56)
  • Jean-Pierre Garnier Ph.D., Independent Director (Age 69)

Has Radius Health been receiving favorable news coverage?

News articles about RDUS stock have trended somewhat positive on Tuesday, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Radius Health earned a news sentiment score of 0.09 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 47.17 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $32.81.

How big of a company is Radius Health?

Radius Health has a market capitalization of $1.50 billion and generates $22.11 million in revenue each year. The biopharmaceutical company earns $-254,230,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Radius Health employs 561 workers across the globe.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]


MarketBeat Community Rating for Radius Health (RDUS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  335 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  531
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Radius Health (NASDAQ:RDUS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Radius Health in the last 12 months. Their average twelve-month price target is $52.10, suggesting that the stock has a possible upside of 59.13%. The high price target for RDUS is $85.00 and the low price target for RDUS is $24.00. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.642.602.562.63
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $52.10$52.00$49.8571$52.1667
Price Target Upside: 59.13% upside53.71% upside31.13% upside35.57% upside

Radius Health (NASDAQ:RDUS) Consensus Price Target History

Price Target History for Radius Health (NASDAQ:RDUS)

Radius Health (NASDAQ:RDUS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018Leerink SwannInitiated CoverageOutperform -> Outperform$53.00MediumView Rating Details
3/23/2018Morgan StanleyLower Price TargetOverweight -> Overweight$61.00 -> $59.00LowView Rating Details
3/22/2018Cantor FitzgeraldSet Price TargetBuy$58.00HighView Rating Details
2/12/2018JPMorgan ChaseLower Price TargetOverweight$70.00 -> $60.00MediumView Rating Details
1/22/2018CitigroupReiterated RatingHold$43.00MediumView Rating Details
11/3/2017Jefferies GroupLower Price TargetHold$38.00 -> $31.00N/AView Rating Details
10/6/2017Goldman SachsReiterated RatingNeutral -> Neutral$45.00N/AView Rating Details
9/29/2017Maxim GroupReiterated RatingPositiveMediumView Rating Details
7/31/2017Canaccord GenuitySet Price TargetBuy$85.00MediumView Rating Details
5/15/2017HC WainwrightReiterated RatingBuy$63.00LowView Rating Details
5/2/2017CowenDowngradeOutperform -> Market PerformLowView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Radius Health (NASDAQ:RDUS) Earnings History and Estimates Chart

Earnings by Quarter for Radius Health (NASDAQ:RDUS)

Radius Health (NASDAQ:RDUS) Earnings Estimates

2018 EPS Consensus Estimate: ($5.17)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.32)($1.32)($1.32)
Q2 20181($1.29)($1.29)($1.29)
Q3 20181($1.30)($1.30)($1.30)
Q4 20181($1.26)($1.26)($1.26)

Radius Health (NASDAQ RDUS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018Q4 2017($1.43)($1.59)$7.37 million$7.66 millionViewListenView Earnings Details
11/2/2017Q3 2017($1.28)($1.31)$6.90 million$13.50 millionViewN/AView Earnings Details
8/3/2017Q2 2017($1.35)($1.58)$1.96 million$0.98 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.1820)($1.32)ViewListenView Earnings Details
2/23/2017Q416($1.34)($1.22)ViewN/AView Earnings Details
11/3/2016Q316($1.03)($1.07)$0.75 millionViewN/AView Earnings Details
8/4/2016Q216($0.95)($1.01)ViewN/AView Earnings Details
5/5/2016Q116($0.74)($0.94)ViewN/AView Earnings Details
2/25/2016Q415($0.64)($0.77)ViewListenView Earnings Details
11/5/2015Q315($0.58)($0.68)ViewN/AView Earnings Details
8/6/2015Q215($0.52)($0.61)ViewN/AView Earnings Details
5/6/2015Q115($0.52)($0.47)ViewN/AView Earnings Details
3/10/2015Q414($0.63)($0.55)ViewN/AView Earnings Details
11/10/2014Q314($0.65)($0.59)ViewN/AView Earnings Details
8/12/2014Q2($0.89)($2.22)$16.24 million$10.62 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Radius Health (NASDAQ:RDUS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Radius Health (NASDAQ RDUS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.00%
Insider Trading History for Radius Health (NASDAQ:RDUS)
Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Radius Health (NASDAQ RDUS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2018Growth N V BiotechMajor ShareholderBuy40,000$33.80$1,352,000.006,050,913View SEC Filing  
4/5/2018Growth N V BiotechMajor ShareholderBuy50,000$36.58$1,829,000.005,903,799View SEC Filing  
3/2/2018Growth N V BiotechMajor ShareholderBuy80,000$32.52$2,601,600.005,853,799View SEC Filing  
2/9/2018Growth N V BiotechMajor ShareholderBuy75,000$34.38$2,578,500.005,773,799View SEC Filing  
11/14/2017Growth N V BiotechMajor ShareholderBuy50,000$26.25$1,312,500.005,698,799View SEC Filing  
11/10/2017Brent Hatzis-SchochVPBuy1,778$28.09$49,944.022,278View SEC Filing  
11/7/2017Jesper HoilandInsiderBuy6,800$29.04$197,472.0012,900View SEC Filing  
11/3/2017Growth N V BiotechMajor ShareholderBuy50,000$29.15$1,457,500.005,648,799View SEC Filing  
10/25/2017Growth N V BiotechMajor ShareholderBuy50,000$32.85$1,642,500.005,548,799View SEC Filing  
9/15/2017Jesper HoilandInsiderBuy6,100$32.72$199,592.006,100View SEC Filing  
9/14/2017Growth N V BiotechMajor ShareholderBuy150,000$33.45$5,017,500.005,448,799View SEC Filing  
9/14/2017Jose CarmonaCFOBuy3,000$32.83$98,490.003,000View SEC Filing  
9/12/2017Growth N V BiotechMajor ShareholderBuy50,000$35.42$1,771,000.005,348,799View SEC Filing  
9/5/2017Growth N V BiotechMajor ShareholderBuy50,000$36.75$1,837,500.005,298,799View SEC Filing  
8/16/2017Growth N V BiotechMajor ShareholderBuy60,000$35.98$2,158,800.005,248,799View SEC Filing  
8/10/2017Growth N V BiotechMajor ShareholderBuy150,000$34.97$5,245,500.005,113,799View SEC Filing  
5/30/2017Growth N V BiotechMajor ShareholderBuy40,000$34.21$1,368,400.005,038,799View SEC Filing  
5/25/2017Growth N V BiotechMajor ShareholderBuy40,000$36.25$1,450,000.004,998,799View SEC Filing  
5/18/2017Growth N V BiotechMajor ShareholderBuy50,000$34.41$1,720,500.004,958,799View SEC Filing  
5/17/2017Growth N V BiotechMajor ShareholderBuy35,000$33.44$1,170,400.004,890,799View SEC Filing  
5/12/2017Growth N V BiotechMajor ShareholderBuy15,000$34.00$510,000.004,873,799View SEC Filing  
5/9/2017Growth N V BiotechMajor ShareholderBuy50,000$35.93$1,796,500.004,858,799View SEC Filing  
5/8/2017Growth N V BiotechMajor ShareholderBuy43,400$35.57$1,543,738.004,785,999View SEC Filing  
5/2/2017Growth N V BiotechMajor ShareholderBuy75,000$33.91$2,543,250.004,765,399View SEC Filing  
5/1/2017Growth N V BiotechMajor ShareholderBuy150,000$35.39$5,308,500.004,690,399View SEC Filing  
3/21/2017Growth N V BiotechMajor ShareholderBuy50,000$35.83$1,791,500.004,540,399View SEC Filing  
3/17/2017Growth N V BiotechMajor ShareholderBuy30,000$38.41$1,152,300.004,490,399View SEC Filing  
3/15/2017Growth N V BiotechMajor ShareholderBuy61,721$39.97$2,466,988.374,415,930View SEC Filing  
3/10/2017Growth N V BiotechMajor ShareholderBuy38,279$39.17$1,499,388.434,398,678View SEC Filing  
1/22/2016Growth N V BiotechMajor ShareholderBuy38,259$31.67$1,211,662.534,360,399View SEC Filing  
1/13/2016Growth N V BiotechMajor ShareholderBuy50,000$39.90$1,995,000.004,322,140View SEC Filing  
11/12/2015Gary HattersleyinsiderSell5,683$75.00$426,225.00View SEC Filing  
11/3/2015Gary HattersleyinsiderSell13,333$70.00$933,310.00View SEC Filing  
10/23/2015Gary HattersleyinsiderSell11,302$65.00$734,630.00View SEC Filing  
10/21/2015Gary HattersleyinsiderSell1,501$65.36$98,105.36View SEC Filing  
10/21/2015Rob WardCEOSell50,000$61.99$3,099,500.00View SEC Filing  
8/21/2015Growth N. V. Biotechmajor shareholderBuy100,000$64.00$6,400,000.004,272,140View SEC Filing  
8/17/2015Kurt GravesDirectorSell22,694$70.00$1,588,580.00View SEC Filing  
7/6/2015Kurt GravesDirectorSell25,000$69.48$1,737,000.00View SEC Filing  
6/18/2015Kurt GravesDirectorSell25,000$55.05$1,376,250.00View SEC Filing  
5/1/2015Growth N V BiotechMajor ShareholderBuy50,000$36.46$1,823,000.00View SEC Filing  
4/29/2015Growth N V BiotechMajor ShareholderBuy50,000$36.23$1,811,500.00View SEC Filing  
4/28/2015Growth N V BiotechMajor ShareholderBuy50,000$36.59$1,829,500.00View SEC Filing  
4/27/2015Growth N V BiotechMajor ShareholderBuy50,000$38.38$1,919,000.00View SEC Filing  
3/6/2015Growth N V BiotechMajor ShareholderBuy75,000$47.08$3,531,000.00View SEC Filing  
2/25/2015Growth N V BiotechMajor ShareholderBuy35,000$45.74$1,600,900.00View SEC Filing  
6/11/2014Morana Jovan-EmbiricosDirectorBuy587,500$8.00$4,700,000.00View SEC Filing  
6/6/2014Growth N V BiotechMajor ShareholderBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Radius Health (NASDAQ RDUS) News Headlines

Source:
DateHeadline
Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10, 2018Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10, 2018
finance.yahoo.com - April 24 at 8:39 AM
Insider Buying: Radius Health (RDUS) Major Shareholder Acquires 40,000 Shares of StockInsider Buying: Radius Health (RDUS) Major Shareholder Acquires 40,000 Shares of Stock
www.americanbankingnews.com - April 23 at 4:24 PM
Radius Health (RDUS) Downgraded to Hold at BidaskClubRadius Health (RDUS) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - April 19 at 12:49 PM
Radius Health Target of Unusually High Options Trading (RDUS)Radius Health Target of Unusually High Options Trading (RDUS)
www.americanbankingnews.com - April 19 at 8:00 AM
Stock Traders Buy High Volume of Call Options on Radius Health (RDUS)Stock Traders Buy High Volume of Call Options on Radius Health (RDUS)
www.americanbankingnews.com - April 19 at 8:00 AM
Radius Health (RDUS) PT Set at $65.00 by Cantor FitzgeraldRadius Health (RDUS) PT Set at $65.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 17 at 10:21 PM
Radius Health (RDUS) Given a $85.00 Price Target by Canaccord Genuity AnalystsRadius Health (RDUS) Given a $85.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 17 at 10:21 PM
Radius Health (RDUS) Expected to Post Quarterly Sales of $13.81 MillionRadius Health (RDUS) Expected to Post Quarterly Sales of $13.81 Million
www.americanbankingnews.com - April 17 at 4:59 AM
Cantor Fitzgerald Reiterates $58.00 Price Target for Radius Health (RDUS)Cantor Fitzgerald Reiterates $58.00 Price Target for Radius Health (RDUS)
www.americanbankingnews.com - April 16 at 10:22 PM
Canaccord Genuity Reiterates "$85.00" Price Target for Radius Health (RDUS)Canaccord Genuity Reiterates "$85.00" Price Target for Radius Health (RDUS)
www.americanbankingnews.com - April 15 at 8:37 AM
 Analysts Anticipate Radius Health (RDUS) to Post -$1.40 EPS Analysts Anticipate Radius Health (RDUS) to Post -$1.40 EPS
www.americanbankingnews.com - April 15 at 3:11 AM
Zacks Investment Research Upgrades Radius Health (RDUS) to HoldZacks Investment Research Upgrades Radius Health (RDUS) to Hold
www.americanbankingnews.com - April 12 at 7:25 PM
Growth N. V. Biotech Acquires 50,000 Shares of Radius Health (RDUS) StockGrowth N. V. Biotech Acquires 50,000 Shares of Radius Health (RDUS) Stock
www.americanbankingnews.com - April 9 at 4:11 PM
Q1 2018 EPS Estimates for Radius Health Decreased by Analyst (RDUS)Q1 2018 EPS Estimates for Radius Health Decreased by Analyst (RDUS)
www.americanbankingnews.com - April 9 at 1:19 AM
UPDATE: Leerink Partners Starts Radius Health (RDUS) at OutperformUPDATE: Leerink Partners Starts Radius Health (RDUS) at Outperform
www.streetinsider.com - April 7 at 8:58 AM
Radius Health Inc (RDUS) Given Average Rating of "Buy" by BrokeragesRadius Health Inc (RDUS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 9:12 AM
Radius Health (RDUS) Lifted to "Hold" at ValuEngineRadius Health (RDUS) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - April 3 at 12:32 AM
Radius Health (RDUS) Down 4.3% Since Earnings Report: Can It Rebound?Radius Health (RDUS) Down 4.3% Since Earnings Report: Can It Rebound?
finance.yahoo.com - April 2 at 9:06 AM
Is Radius Health Worth Your Time?Is Radius Health Worth Your Time?
seekingalpha.com - March 31 at 8:38 AM
 Analysts Expect Radius Health Inc (RDUS) Will Post Quarterly Sales of $13.71 Million Analysts Expect Radius Health Inc (RDUS) Will Post Quarterly Sales of $13.71 Million
www.americanbankingnews.com - March 31 at 4:16 AM
Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male OsteoporosisRadius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis
finance.yahoo.com - March 30 at 5:11 PM
Radius Health (RDUS) Raised to "Hold" at BidaskClubRadius Health (RDUS) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - March 29 at 3:36 PM
Radius Health (RDUS) Now Covered by Leerink SwannRadius Health (RDUS) Now Covered by Leerink Swann
www.americanbankingnews.com - March 29 at 8:36 AM
 Analysts Anticipate Radius Health Inc (RDUS) Will Announce Earnings of -$1.42 Per Share Analysts Anticipate Radius Health Inc (RDUS) Will Announce Earnings of -$1.42 Per Share
www.americanbankingnews.com - March 29 at 5:17 AM
Radius Health (RDUS) Given "Hold" Rating at CitigroupRadius Health (RDUS) Given "Hold" Rating at Citigroup
www.americanbankingnews.com - March 27 at 10:27 AM
Radius Health Down on Negative CHMP Opinion for Lead DrugRadius Health Down on Negative CHMP Opinion for Lead Drug
finance.yahoo.com - March 23 at 5:18 PM
Morgan Stanley Lowers Radius Health (RDUS) Price Target to $59.00Morgan Stanley Lowers Radius Health (RDUS) Price Target to $59.00
www.americanbankingnews.com - March 23 at 4:34 PM
Waltham’s Radius Health says osteoporosis drug rejected in EuropeWaltham’s Radius Health says osteoporosis drug rejected in Europe
finance.yahoo.com - March 22 at 5:16 PM
Radius Health (RDUS) Given a $58.00 Price Target at Cantor FitzgeraldRadius Health (RDUS) Given a $58.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - March 22 at 11:52 AM
Quotidian Technical Highlights on Selected Biotech Stocks -- Portola Pharma, Protalix BioTherapeutics, Radius Health ... - PR Newswire (press release)Quotidian Technical Highlights on Selected Biotech Stocks -- Portola Pharma, Protalix BioTherapeutics, Radius Health ... - PR Newswire (press release)
www.prnewswire.com - March 20 at 5:00 PM
Radius Health Announces Positive Data on Lead Drug Tymlos - NasdaqRadius Health Announces Positive Data on Lead Drug Tymlos - Nasdaq
www.nasdaq.com - March 20 at 5:00 PM
Radius Health (RDUS) Announces Positive Data for ACTIVExtend BMD Responder Analysis for TYMLOS ... - StreetInsider.comRadius Health (RDUS) Announces Positive Data for ACTIVExtend BMD Responder Analysis for TYMLOS ... - StreetInsider.com
www.streetinsider.com - March 19 at 8:48 AM
Radius Health Presents Positive Data From ACTIVExtend BMD Responder Analysis - NasdaqRadius Health Presents Positive Data From ACTIVExtend BMD Responder Analysis - Nasdaq
www.nasdaq.com - March 18 at 6:00 PM
Commit To Purchase Radius Health At $22.50, Earn 8.7 ... - Nasdaq - NasdaqCommit To Purchase Radius Health At $22.50, Earn 8.7 ... - Nasdaq - Nasdaq
www.nasdaq.com - March 16 at 8:49 AM
Zacks: Brokerages Anticipate Radius Health Inc (RDUS) Will Post Quarterly Sales of $13.71 MillionZacks: Brokerages Anticipate Radius Health Inc (RDUS) Will Post Quarterly Sales of $13.71 Million
www.americanbankingnews.com - March 14 at 8:38 AM
Radius Health (RDUS) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowRadius Health (RDUS) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 12 at 6:15 PM
Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) InjectionRadius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection
finance.yahoo.com - March 12 at 6:15 PM
Radius Health Inc (RDUS) Given Consensus Rating of "Hold" by BrokeragesRadius Health Inc (RDUS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 10 at 7:36 AM
Radius Health Inc (RDUS) Major Shareholder Growth N. V. Biotech Purchases 80,000 SharesRadius Health Inc (RDUS) Major Shareholder Growth N. V. Biotech Purchases 80,000 Shares
www.americanbankingnews.com - March 6 at 6:14 PM
Radius Health to Present at the Cowen 38th Annual Health Care ConferenceRadius Health to Present at the Cowen 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 8:38 AM
Prosight Management LP Takes $3.50 Million Position in Radius Health Inc (RDUS)Prosight Management LP Takes $3.50 Million Position in Radius Health Inc (RDUS)
www.americanbankingnews.com - March 5 at 2:55 PM
Radius (RDUS) Q4 Loss Wider Than Expected on Higher Expenses - NasdaqRadius (RDUS) Q4 Loss Wider Than Expected on Higher Expenses - Nasdaq
www.nasdaq.com - March 3 at 8:38 AM
Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business ... - GlobeNewswire (press release)Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business ... - GlobeNewswire (press release)
globenewswire.com - March 3 at 8:38 AM
Radius Health (RDUS) Price Target Raised to $61.00 at Morgan StanleyRadius Health (RDUS) Price Target Raised to $61.00 at Morgan Stanley
www.americanbankingnews.com - March 2 at 10:03 PM
Heres Why Radius Health Dropped as Much as 14.7% TodayHere's Why Radius Health Dropped as Much as 14.7% Today
www.msn.com - March 2 at 5:47 PM
Here's Why Radius Health Dropped as Much as 14.7% TodayHere's Why Radius Health Dropped as Much as 14.7% Today
finance.yahoo.com - March 2 at 5:47 PM
Radius Health (RDUS) Announces Quarterly  Earnings Results, Misses Estimates By $0.16 EPSRadius Health (RDUS) Announces Quarterly Earnings Results, Misses Estimates By $0.16 EPS
www.americanbankingnews.com - March 1 at 9:12 PM
Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business UpdateRadius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business Update
finance.yahoo.com - March 1 at 5:32 PM
Radius Health Inc to Host Earnings CallRadius Health Inc to Host Earnings Call
finance.yahoo.com - March 1 at 5:32 PM
Radius Health Inc (RDUS) Shares Bought by Hudson Bay Capital Management LPRadius Health Inc (RDUS) Shares Bought by Hudson Bay Capital Management LP
www.americanbankingnews.com - February 28 at 1:47 PM

SEC Filings

Radius Health (NASDAQ:RDUS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Radius Health (NASDAQ:RDUS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Radius Health (NASDAQ RDUS) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.